This company listing is no longer active
Swedish Orphan Biovitrum Balance Sheet Health
Financial Health criteria checks 1/6
Swedish Orphan Biovitrum has a total shareholder equity of SEK28.4B and total debt of SEK27.8B, which brings its debt-to-equity ratio to 98.1%. Its total assets and total liabilities are SEK75.8B and SEK47.4B respectively. Swedish Orphan Biovitrum's EBIT is SEK4.8B making its interest coverage ratio 8.6. It has cash and short-term investments of SEK790.0M.
Key information
98.1%
Debt to equity ratio
SEK 27.82b
Debt
| Interest coverage ratio | 8.6x |
| Cash | SEK 790.00m |
| Equity | SEK 28.38b |
| Total liabilities | SEK 47.41b |
| Total assets | SEK 75.78b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SOBI BTA's short term assets (SEK10.8B) do not cover its short term liabilities (SEK18.4B).
Long Term Liabilities: SOBI BTA's short term assets (SEK10.8B) do not cover its long term liabilities (SEK29.0B).
Debt to Equity History and Analysis
Debt Level: SOBI BTA's net debt to equity ratio (95.3%) is considered high.
Reducing Debt: SOBI BTA's debt to equity ratio has increased from 0.03% to 98.1% over the past 5 years.
Debt Coverage: SOBI BTA's debt is not well covered by operating cash flow (18.2%).
Interest Coverage: SOBI BTA's interest payments on its debt are well covered by EBIT (8.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/27 23:56 |
| End of Day Share Price | 2023/09/26 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Lindström | ABG Sundal Collier |
| Rosie Turner | Barclays |
| Brian Balchin | Barclays |